{"entity": "publication", "iuid": "6a0d0fc1945c47a1a4be165261e2ecb9", "timestamp": "2026-08-26T22:46:49.708Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/6a0d0fc1945c47a1a4be165261e2ecb9.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/6a0d0fc1945c47a1a4be165261e2ecb9"}}, "title": "The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors.", "authors": [{"family": "Nico\u015b", "given": "Marcin", "initials": "M"}, {"family": "Krawczyk", "given": "Pawe\u0142", "initials": "P"}, {"family": "Crosetto", "given": "Nicola", "initials": "N"}, {"family": "Milanowski", "given": "Janusz", "initials": "J"}], "type": "journal article", "published": "2020-12-04", "journal": {"title": "Front Oncol", "issn": "2234-943X", "volume": "10", "pages": "569202", "issn-l": "2234-943X"}, "abstract": "Immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches in metastatic non-small cell lung cancer (M-NSCLC). Unfortunately, approximately 50-75% of patients do not respond to this treatment modality. Intratumor heterogeneity (ITH) at the genetic and phenotypic level is considered as a major cause of anticancer therapy failure, including resistance to ICIs. Recent observations suggest that spatial heterogeneity in the composition and spatial organization of the tumor microenvironment plays a major role in the response of M-NSCLC patients to ICIs. In this mini review, we first present a brief overview of the use of ICIs in M-NSCLC. We then discuss the role of genetic and non-genetic ITH on the efficacy of ICIs in patients with M-NSCLC.", "doi": "10.3389/fonc.2020.569202", "pmid": "33344229", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7746867"}], "notes": [], "created": "2026-08-21T13:00:18.850Z", "modified": "2026-08-21T13:00:18.865Z"}